Premium
Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications
Author(s) -
Doucet Christelle,
Ernou Isabelle,
Zhang Yizhou,
Llense JeanRoch,
Begot Laurent,
Holy Xavier,
Lataillade JeanJacques
Publication year - 2005
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.20391
Subject(s) - mesenchymal stem cell , subculture (biology) , basic fibroblast growth factor , growth factor , platelet lysate , microbiology and biotechnology , platelet , in vitro , fetal bovine serum , chondrogenesis , cell therapy , immunology , transforming growth factor , stem cell , biology , biochemistry , receptor
Mesenchymal stem cells (MSCs) are considered as emergent “universal” cells and various tissue repair programs using MSCs are in development. In vitro expansion of MSCs is conventionally achieved in medium containing fetal calf serum (FCS) and is increased by addition of growth factors. However, for widespread clinical applications, contact of MSCs with FCS must be minimized since it is a putative source of prion or virus transmission. Therefore, because platelets are a natural source of growth factors, we sought to investigate in vitro MSC expansion in response to platelet lysates (PL) obtained from platelet‐rich plasma. Human MSCs were expanded in FCS (±bFGF)‐ or PL‐supplemented medium through a process of subculture. We demonstrated that PL‐containing medium is enriched by growth factors (platelet‐derived growth factors (PDGFs), basic fibroblast growth factor (bFGF), transforming growth factor (TGF‐β), insulin‐like growth factor‐1 (IGF‐1) …) and showed that PL is able to promote MSC expansion, to decrease the time required to reach confluence, and to increase CFU‐F size, as compared to the FCS medium. Furthermore, we demonstrated that MSCs cultured in the presence of PL maintain their osteogenic, chondrogenic, and adipogenic differentiation properties and retain their immunosuppressive activity. Therefore, we propose that PL may be a powerful and safe substitute for FCS in development of tissue‐ and cellular‐engineered products in clinical settings using MSCs. © 2005 Wiley‐Liss, Inc.